Genotropin MiniQuick (Somatropin)

What Is Genotropin MiniQuick and What Is It Used For?

Genotropin MiniQuick contains somatropin, a recombinant human growth hormone that has the same amino acid sequence as the growth hormone naturally produced by the pituitary gland. Growth hormone is essential for normal bone and muscle growth, and it plays a critical role in regulating fat distribution, body composition, and metabolic processes throughout life. The term "recombinant" means that it is produced by genetically engineered Escherichia coli bacteria using recombinant DNA technology — it is not derived from human or animal tissue.

The MiniQuick delivery system is specifically designed as a single-dose, disposable prefilled syringe. Each device contains a two-chamber cartridge with the growth hormone powder in one compartment and the diluent (sterile water with mannitol) in the other. When the plunger rod is twisted clockwise, the two compartments mix automatically, eliminating the need for separate reconstitution steps. This design makes Genotropin MiniQuick particularly convenient for patients who travel frequently or who prefer a simpler injection process.

Indications in Children

Genotropin MiniQuick is approved for the treatment of several growth disorders in pediatric patients. Each indication requires careful diagnosis and monitoring by a physician experienced in growth hormone therapy:

• Growth hormone deficiency (GHD): Children who do not produce sufficient amounts of their own growth hormone and therefore do not grow at a normal rate. Diagnosis is confirmed through stimulation testing and clinical assessment. If growth hormone deficiency persists into adolescence and early adulthood, treatment may be continued through the transition period until physical maturation is complete.
• Turner syndrome: A chromosomal condition affecting girls (complete or partial absence of one X chromosome) that frequently causes short stature. Growth hormone therapy in Turner syndrome has been shown to increase final adult height by an average of 5–8 cm in clinical trials.
• Chronic kidney disease (CKD): Impaired kidney function can significantly affect growth in children. Growth hormone therapy is indicated for children with CKD who demonstrate growth failure, and treatment should continue until kidney transplantation or until the child reaches final height.
• Prader-Willi syndrome (PWS): A genetic disorder characterized by poor muscle tone, short stature, cognitive impairment, and insatiable appetite. Growth hormone therapy improves linear growth, body composition (reducing fat mass and increasing lean body mass), muscle strength, and physical function in children with PWS.
• Small for gestational age (SGA): Children born significantly smaller or lighter than expected for their gestational age who have not achieved catch-up growth by age 4 years or later. Growth hormone treatment can help these children reach a more normal height trajectory.

Indications in Adults

In adult patients, Genotropin MiniQuick is indicated for the treatment of significant growth hormone deficiency. This may arise in two clinical scenarios: growth hormone deficiency that began in childhood and continues into adult life (childhood-onset GHD), or growth hormone deficiency acquired in adulthood due to pituitary disease, surgery, radiation therapy, or other hypothalamic-pituitary conditions (adult-onset GHD).

Adults with growth hormone deficiency often experience reduced quality of life, increased body fat (particularly abdominal fat), decreased lean muscle mass, reduced bone mineral density, adverse lipid profiles, and diminished exercise capacity. Growth hormone replacement therapy has been demonstrated to improve body composition, increase bone density, enhance cardiovascular risk markers, and improve overall well-being and quality of life in these patients.

For patients who received growth hormone therapy during childhood, growth hormone production is retested after completion of linear growth. If significant deficiency is confirmed, the treating physician will recommend continuation of therapy into adulthood, as the metabolic benefits of growth hormone extend beyond skeletal growth.

What Should You Know Before Taking Genotropin MiniQuick?

Contraindications

Genotropin MiniQuick must not be used in the following situations. Inform your doctor immediately if any of these apply to you:

• Hypersensitivity: If you are allergic to somatropin or any of the excipients in Genotropin MiniQuick (glycine, mannitol, sodium dihydrogen phosphate, disodium phosphate).
• Active malignancy: Active tumors or cancer of any type. Tumors must be inactive and cancer treatment must be completed before growth hormone therapy can be initiated. Growth hormone is not known to cause cancer, but it should not be used in the presence of active malignant disease.
• Acute critical illness: Serious illness such as complications following open heart surgery, abdominal surgery, acute respiratory failure, or major trauma. Studies have shown increased mortality in critically ill adult patients receiving high-dose growth hormone, and therefore it is contraindicated in these settings.
• Closed epiphyses: If the medicine has been prescribed to stimulate growth and the growth plates have already fused (i.e., the patient has stopped growing), growth hormone will not increase height and should not be used for this purpose.

Warnings and Precautions

Tell your doctor before starting treatment if any of the following conditions apply to you or your child. Careful monitoring and possible dose adjustments may be necessary:

• Diabetes or risk of diabetes: Growth hormone can affect insulin sensitivity and glucose metabolism. Blood sugar levels should be monitored regularly during treatment. In patients with pre-existing diabetes mellitus, insulin or oral antidiabetic drug doses may need adjustment.
• Thyroid function: Growth hormone therapy may unmask previously undiagnosed hypothyroidism or worsen existing subclinical hypothyroidism. Thyroid function should be tested regularly, and thyroid hormone replacement may need to be initiated or adjusted.
• Adrenal insufficiency: Patients receiving glucocorticoid replacement therapy should be monitored carefully, as growth hormone may reduce the effectiveness of cortisol. Glucocorticoid doses may need to be adjusted to prevent adrenal crisis.
• Intracranial hypertension: Increased intracranial pressure with symptoms including severe headache, visual disturbances, or vomiting has been reported in patients receiving growth hormone. If these symptoms develop, contact your doctor immediately. The condition is usually reversible upon dose reduction or discontinuation.
• Hip pain or limping: Children receiving growth hormone who develop hip or knee pain or begin limping should be evaluated promptly for slipped capital femoral epiphysis (SCFE) and Legg-Calvé-Perthes disease, which are more common during periods of rapid growth.
• History of tumors: Patients with a history of malignancy should undergo regular monitoring for tumor recurrence. While growth hormone does not appear to increase the rate of new tumors, surveillance is important.
• Pancreatitis: Although rare, pancreatitis has been reported in patients treated with growth hormone, particularly in children. Contact your doctor if you experience severe abdominal pain.
• Elderly patients (over 80 years): Experience in patients over 80 years is limited. Older patients may be more sensitive to somatropin and may require lower doses.

Special Populations

Children with chronic kidney disease: Kidney function and growth rate should be assessed before starting treatment. Treatment for the underlying kidney condition should continue as prescribed. Growth hormone therapy should be discontinued at the time of kidney transplantation.

Children with Prader-Willi syndrome: Before starting treatment, your doctor will assess for signs of upper airway obstruction, sleep apnea, and respiratory infection. If signs of respiratory compromise develop during treatment (including new or increased snoring), the patient should be evaluated and treatment may need to be interrupted. Dietary guidance should be followed strictly to manage weight. Scoliosis monitoring is also recommended during therapy. Children with severe obesity or severe respiratory impairment should not receive growth hormone therapy.

Children born small for gestational age (SGA): For children aged 9–12 years, the treating physician should discuss puberty and treatment considerations. Blood glucose and insulin levels should be monitored before treatment and annually thereafter. Treatment should continue until the child reaches final adult height or until an adequate growth response is no longer achieved.

Pregnancy and Breastfeeding

Genotropin MiniQuick should not be used during pregnancy or if you suspect you may be pregnant or are trying to become pregnant. If you become pregnant while receiving treatment, stop the medication and contact your doctor immediately. There is insufficient data on the effects of somatropin on fetal development in humans.

Consult your doctor before using Genotropin MiniQuick while breastfeeding. It is not known whether somatropin is excreted in human breast milk, and a decision should be made regarding whether to discontinue breastfeeding or discontinue the medication, taking into account the clinical importance of treatment to the mother.

Driving and Operating Machinery

Genotropin MiniQuick has no known effect on the ability to drive or operate machinery.

Sodium Content

This medicine contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free. This is important for patients on sodium-restricted diets.

How Does Genotropin MiniQuick Interact with Other Drugs?

Growth hormone influences multiple metabolic pathways, and its interaction with other medications is clinically important. Always inform your doctor or pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medicines, and herbal supplements. The following interactions are particularly significant:

The interaction with oral estrogen deserves special attention. Women receiving oral estrogen replacement therapy (such as hormone replacement therapy or oral contraceptives) may require significantly higher doses of growth hormone to achieve the same therapeutic effect. This is because oral estrogen increases hepatic first-pass metabolism and reduces the liver's ability to produce IGF-1 in response to growth hormone. Women who switch from oral to transdermal estrogen delivery may be able to reduce their growth hormone dose.

For patients on glucocorticoid replacement therapy (such as hydrocortisone or prednisolone for adrenal insufficiency), regular monitoring is essential. Growth hormone can enhance the conversion of cortisone to cortisol in the liver, which may unmask previously adequate cortisol replacement as insufficient. Your endocrinologist will monitor cortisol levels and adjust replacement doses accordingly.

What Is the Correct Dosage of Genotropin MiniQuick?

The dose of Genotropin MiniQuick is carefully individualized by your doctor based on your weight, height, the condition being treated, and how well you respond to the hormone. All patients are different, and treatment protocols are adjusted to achieve optimal outcomes while minimizing side effects. Never change your dose or treatment schedule without consulting your doctor.

Pediatric Dosing

Adult Dosing

Adult growth hormone replacement requires a careful, individualized approach with gradual dose titration based on clinical response and IGF-1 levels:

Doses should be reviewed every 6 months. Your doctor will monitor IGF-1 levels to ensure they remain within the age- and sex-appropriate normal range, which helps optimize efficacy while minimizing the risk of side effects.

How to Inject Genotropin MiniQuick

Genotropin MiniQuick is injected subcutaneously (under the skin), meaning the needle is inserted through a short injection needle into the fatty tissue just beneath the skin. Your doctor or nurse should provide thorough instructions on the correct injection technique before you begin self-administering. Do not inject yourself until you are confident in the procedure.

1. Prepare: Remove the syringe from the refrigerator 30 minutes before injection to allow it to reach room temperature, making the injection more comfortable. Wash your hands thoroughly and clean the injection site with an alcohol swab.
2. Attach the needle: Peel off the protective paper from the needle and place it straight over the rubber stopper. Screw it on clockwise until it stops.
3. Mix the solution: Hold the MiniQuick with the needle pointing upward. Turn the plunger rod clockwise as far as it will go. Do NOT shake — gently swirl if needed. Check that the solution is clear and particle-free.
4. Remove needle caps: Remove both the outer and inner needle caps.
5. Inject: Lift a skin fold at the injection site (thigh or buttock). Insert the needle and push the plunger rod all the way in. Wait a few seconds before withdrawing.
6. Dispose: Do not recap the needle. Dispose of the entire device in a sharps container.

Inject at approximately the same time each day. Bedtime is recommended because it mimics the body's natural pattern of higher growth hormone secretion during sleep. Rotate injection sites between the thighs and buttocks to prevent lipodystrophy (thinning or thickening of the fatty tissue at the injection site).

Missed Dose

If you forget to take your daily injection, do not take a double dose to make up for the missed one. Simply take your next dose at the regular scheduled time the following day. Note any missed doses and inform your doctor at your next follow-up appointment, as frequent missed doses can reduce the effectiveness of treatment.

Overdose

Stopping Treatment

Do not stop taking Genotropin MiniQuick without consulting your doctor. Abrupt discontinuation may lead to a return of growth hormone deficiency symptoms, including changes in body composition, reduced energy levels, and adverse metabolic effects. Your doctor will advise on the appropriate course of action if discontinuation is being considered.

What Are the Side Effects of Genotropin MiniQuick?

Like all medicines, Genotropin MiniQuick can cause side effects, although not everyone experiences them. Many of the common side effects in adults occur during the first months of treatment and may resolve on their own or after a dose reduction. If you experience any side effects that are persistent, worsening, or concerning, contact your doctor.

Adults

Children

Injection-Site Reactions

The skin at the injection site may become dimpled or uneven (lipodystrophy) if you repeatedly inject in the same location. This can be prevented by rotating injection sites with each dose, alternating between the left and right thigh and buttock areas. If lipodystrophy develops, avoid injecting in the affected area until it has fully recovered.

Special Safety Concerns

Prader-Willi syndrome: Isolated cases of sudden death have been reported in patients with Prader-Willi syndrome treated with growth hormone. However, no causal relationship has been established. The reported cases typically involved patients with severe obesity, a history of upper airway obstruction, sleep apnea, or unidentified respiratory infection. Patients with PWS should be carefully evaluated for respiratory risk factors before and during treatment.

Hip and knee pain in children: Children who experience discomfort or pain in the hip or knee during growth hormone treatment should be promptly evaluated. Slipped capital femoral epiphysis (SCFE) and Legg-Calvé-Perthes disease can occur more frequently during periods of rapid growth, and early detection is important for optimal outcomes.

Metabolic effects: Growth hormone therapy can cause elevated blood glucose levels and reduced thyroid hormone levels. Your doctor will monitor blood sugar and thyroid function through regular blood tests and prescribe appropriate treatment if needed. In rare cases, pancreatitis (inflammation of the pancreas) has been reported, particularly in children.

How Should You Store Genotropin MiniQuick?

Proper storage is essential to maintain the potency and safety of Genotropin MiniQuick. The medication contains a protein (somatropin) that can be damaged by improper temperature exposure, light, or mechanical agitation. Follow these storage guidelines carefully:

Before Reconstitution (Unmixed)

• Primary storage: Store in a refrigerator at 2–8°C (36–46°F). Do not freeze.
• Light protection: Keep the syringe in the outer carton to protect from light.
• Room temperature option: Unopened packages may be stored outside the refrigerator for up to 6 months at temperatures not exceeding 25°C (77°F). Record the date removed from refrigeration and the new expiry date (6 months from removal or the original expiry date, whichever comes first) on the outer carton.
• Important: Once removed from the refrigerator, do not return the product to refrigerated storage. If the medicine is not used within the 6-month room temperature period, it must be discarded.

After Reconstitution (Mixed)

• Preferred: Use immediately after mixing.
• If not used immediately: Store in the refrigerator at 2–8°C and use within 24 hours.
• Do not freeze the reconstituted solution.
• Keep in the outer carton to protect from light.

General Precautions

• Keep out of sight and reach of children.
• Do not use after the expiry date printed on the carton (month/year). The expiry date refers to the last day of that month.
• Do not use if you see particles or if the reconstituted solution is not clear.
• Dispose of used needles and empty syringes in an appropriate sharps disposal container — never in household waste.
• Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer in use to help protect the environment.

What Does Genotropin MiniQuick Contain?

Active Ingredient

The active substance is somatropin, a recombinant human growth hormone produced in Escherichia coli cells using recombinant DNA technology. Each single-dose syringe contains one of the following strengths of somatropin after reconstitution:

Inactive Ingredients (Excipients)

Powder compartment: Glycine (E640), mannitol (E421), anhydrous sodium dihydrogen phosphate (E339), and anhydrous disodium phosphate (E339).

Solvent compartment: Water for injections and mannitol (E421).

Appearance and Packaging

Genotropin MiniQuick is presented as a powder and solvent for solution for injection in a two-chamber cartridge contained within a disposable prefilled syringe. The powder is white and the solvent is a clear liquid. The cartridge contains the powder in one compartment and the solvent in the other, separated until the plunger rod is twisted to initiate mixing.

Pack sizes: 4, 7, or 28 syringes per box. Not all strengths and pack sizes may be marketed in all countries.